China’s NMPA approves GSK’s Nucala for CRSwNP treatment
The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with ...
GSK’s Nucala Gains Approval in China for CRSwNP
GlaxoSmithKline ( (GSK) ) has provided an update. GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with ...
Daily6d
GSK Nucala approved in China for treatment of adults with chronic rhinosinusitis with nasal polyps
London: GSK plc has announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a ...
Pharmabiz6d
GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps
GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps: London, UK Saturday, January 4, 2025, 09:00 Hrs [IST] GSK plc announced ...
MARKET REPORT: Airlines lose altitude as higher fuel costs bite
EasyJet was a big FTSE 100 faller, down 3.1 per cent, or 17p, to 540.4p and British Airways owner IAG - a top blue-chip gainer in 2024 - shed 1.2 per cent, or 3.7p, to 298.9p.
FiercePharma6d
Regulatory tracker: NICE endorses AZ's Lynparza in BRCA-mutated breast cancer
Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. | In this tracker, Fierce Pharma is recording the ...